SOURCE: Depomed, Inc.

October 26, 2010 07:00 ET

Depomed to Announce Third Quarter 2010 Financial Results on November 1, 2010

MENLO PARK, CA--(Marketwire - October 26, 2010) - Depomed, Inc. (NASDAQ: DEPO) announced today that it will release third quarter 2010 financial results after the market closes on Monday, November 1, 2010. The company will host a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results.

The conference call will be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.


About Depomed

Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Abbott Products, Inc. A New Drug Application for DM-1796 was accepted by the FDA in the second quarter of 2010. Product candidate SeradaTM is in Phase 3 clinical development for menopausal hot flashes. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of Acuform- enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Additional information about Depomed may be found on its website, www.depomed.com.


[HUG#1455121]


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Depomed, Inc. via Thomson Reuters ONE

Contact Information

  • CONTACT:
    Sheilah Serradell
    Depomed, Inc.
    650-462-5900
    Email Contact